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Eﬃcient synthesis of small-sized phosphonated
dendrons: potential organic coatings of iron oxide
nanoparticles†
Antonio Garofalo,‡ Audrey Parat,‡ Catalina Bordeianu, Cynthia Ghobril,
Marie Kueny-Stotz, Aure´lie Walter, Julien Jouhannaud, Sylvie Begin-Colin and
Delphine Felder-Flesch*
We report herein the synthesis of biocompatible small-sized phosphonated monomers and dendrons used
as functional coatings of metal oxide nanoparticles, more specifically superparamagnetic iron oxides
(SPIOs) for magnetic resonance imaging (MRI) and therapy through hyperthermia. The molecules were
engineered to modulate their size, their hydrophilic and/or biocompatible character (poly(amido)amine
versus oligoethyleneglycol), the number of anchoring phosphonate groups (monophosphonate versus
phosphonic tweezers) and the number of peripheral functional groups for further grafting of dyes or
specific vectors. Such a library of hydrophilic phosphonic acids opens new possibilities for the
investigation of dendronized nanohybrids as theranostics.
Introduction
Research on inorganic nanoparticles (NPs) is rapidly expanding
with a large variety of applications, as well as strategies for
their synthesis.1 Most often, surface modification of the NPs is
critical, in particular to avoid their aggregation, make them
dispersible in liquid media or derivatize them with functional
end groups for further modification. Here again, the excep-
tional binding properties of phosphonic acids to oxide surfaces
have attracted much attention and many examples of decorated
magnetic metal oxide NPs using phosphonate terminated
molecules have recently emerged in the literature.2
Many research groups worldwide are actively developing
superparamagnetic iron oxide (SPIO) NPs with the emergence
of a vast number of applications in health sciences, including
for example combined in vivo magnetic resonance imaging
(MRI) and optical imaging via multimodal NPs based on
fluorescent probes conjugated to SPIO NPs,3 hyperthermic
heating of tumours,4 and drug delivery.5 In this context, bio-
functionalization of the NPs is most often required to avoid
aggregation or rapid clearance by the Mononuclear Phagocyte
System.6 For this purpose, appropriate coatings and especially
surface modification using molecules derivatized with phosphonic
acid groups are being developed. It is also worth noting that
bisphosphonate anchors were found to bind more strongly to iron
oxide NPs than monophosphonates, thus conferring them higher
stability in water at physiological pH.7
Among the most common routes to functional phosphonic
acids for surface modification are the Michaelis–Arbuzov
and Michaelis–Becker reactions,8 hydrophosphonylation with
palladium (Tanaka’s9 or Beletskaya’s10 methods) or with
nickel or copper,11 the Hirao cross-coupling,12 the phospha-
Michael addition,13 and the Pudovik reaction14 starting from
aldehydes. The Michaelis–Arbuzov reaction,15 also known as
the Arbuzov reaction, is one of the most versatile reactions for
the formation of P–C bonds and consists of the reaction of
a triester phosphite with an alkyl halide, resulting in the
conversion of P(III) to a pentavalent phosphorus species.
While elevated temperatures are required for the activation
of the transformation, recent data have shown that for some
specific substrates this reaction can be advantageously oper-
ated at room temperature in the presence of a suitable Lewis
acid.16 Barney et al.17 recently proposed a straightforward
synthesis of benzyl or allyl phosphonates from the corre-
sponding alcohols using triethylphosphite and zinc iodide.
Benzyl phosphonates esters are usually prepared from benzyl
halides and trialkylphosphite via an Arbuzov reaction and
this procedure is a convenient alternative, although benzylic
compounds bearing an electron-withdrawing group are much
less reactive. Moreover, such synthetic methodology allows
introducing the phosphonate group in the last steps of the
synthesis, which is advantageous since the chromatographic
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purification of phosphonate-containing intermediates through-
out the whole multistep synthesis is time-consuming.
Dendrimers or dendritic architectures18 are being devel-
oped for biomedical applications due to their precisely
defined structure and composition, and high tuneable surface
chemistry.19 A clear input is brought by the dendritic mole-
cules as they are discrete and monodisperse entities in which
size, hydrophilicity, molecular weight and biocompatibility
can easily be tuned as a function of their generation.20
Furthermore, a dendritic shell allows versatile and reproduci-
ble polyfunctionalization at its periphery which could lead to,
multimodal imaging probes through dye or fluorophore graft-
ing, and theranostics through specific drug anchoring.
Current studies show that small-sized dendrons may have an
impressive future in the functionalization of magnetic nano-
particles21 due to their highly controlled molecular structure
and high tuneability leading to biocompatible, polyfunctional
and water-soluble systems. Dendronized iron oxide nano-
particles using a phosphonate or hydroxamic acid anchor
were shown to display very good colloidal properties and high
relaxivity values.22 Such anchoring groups induced strong
binding,23 and phosphonic anchors were demonstrated to
preserve NPs’ magnetic properties.24
We recently reported that a dendritic coating (Fig. 1) of
magnetic metal oxide nanoparticles increases their eﬀect on
water proton relaxation times thus leading to optimized
contrast enhancement capacities in MRI.25
Therefore, we managed to prepare a library of functional
dendritic phosphonic acids either fully PEGylated (Part I) or
derived from the poly(amido)amine (PAMAM) family (Part II). In
both parts, the generation, the OEG chain length and the number
of phosphonic anchors (mono-phosphonate or bisphosphonate
tweezers) were varied. Such a library of functional hydrophilic
phosphonic acids opens new possibilities for the investiga-
tion of dendronized nanohybrids as possible theranostics
(Scheme 1).
Results and discussion
Part I: PEGylated monomers
Synthesis of mono-ethylphosphonate. We have previously
developed the synthesis of first generation monophosphonate
oligoethylene glycol (OEG) gallate dendrons (G1-P1-OEG) 1–4
(Fig. 1) bearing a longer functionalized OEG chain in the para
position for further grafting of biomolecules.26 These small-
sized monomers were obtained from the key intermediate 12
which was obtained in six steps with a 25% overall yield
(Scheme 2). First, para-benzylated methyl gallate 6 and tosy-
lated tetraethyleneglycol monomethyl ether 5 were obtained in
good yields from the commercially available methyl gallate and
tetraethyleneoxide monomethyl ether, respectively, following a
reported one-step procedure.27 A Williamson etherification
between 5 and 6 in acetone at 60 1C, in the presence of
potassium carbonate (K2CO3) and potassium iodide (KI),
allowed the preparation of ester 7 in 75% yield. Protected ethyl
phosphonate 11 was obtained following a three-step sequence:
(i) reduction of the ester function by lithium aluminium
hydride (LiAlH4) to obtain benzylic alcohol 9 in 90% yield,
(ii) treatment of 9 with thionyl chloride (SOCl2) to yield benzyl
chloride 10 (70%) and (iii) refluxing 10 at 160 1C in triethyl
phosphate (P(OEt)3) to prepare para-protected ethyl phospho-
nate 11 (85%). Finally, phenol deprotection was achieved by
hydrogenolysis in the presence of palladium activated on
carbon (Pd/C) (10%) which led, after overnight stirring, to ethyl
phosphonate 12 in 96% yield.
Finally, monomers 1–4 (Fig. 1) were obtained after deprotec-
tion of the phosphonate esters with a large excess of trimethyl-
silyl bromide (TMSBr).21
The synthesis of ethyl phosphonate 15 displaying an ethyl-
amine linker in the para-position is highlighted in Scheme 3.
The compound was obtained in 4 steps with 54% overall yield.Fig. 1 Structure of phosphonic acid derivatives previously described.26
Scheme 1 General structure of synthesized compounds.
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First, 4-(benzyloxy) benzyl chloride reacted under reflux with
P(OEt)3 to yield 13 (92%). Phenol 14 was obtained after hydro-
genolysis in the presence of Pd/C (10%), and was next engaged
in an etherification reaction in the presence of Boc-2-bromo-
ethylamine. Subsequent treatment with trifluoroacetic acid
(TFA) yielded 15 (94%).
Synthesis of bis-amino mono-ethylphosphonate. The synthetic
route of the key intermediate 18 for the preparation of dendritic
ethyl phosphonate is reported in Scheme 4. Benzyl bromide 16
was obtained in 84% yield from the commercially available
3,5-dihydroxybenzyl alcohol after its activation with triphenyl
phosphine (PPh3) and tetrabromomethane (CBr4). Compound 16
was immediately converted to its corresponding ethyl phosphonate
17 after refluxing for 2 hours in P(OEt)3. An etherification reaction
between 17 and Boc-2-bromoethylamine, followed by the deprotec-
tion of the two amine functions in the presence of TFA, provided 18
as a ditrifluoroacetate salt (59% yield over 2 steps).
Synthesis of mono-amino bis-ethylphosphonate tweezers.
The synthesis of tweezers 22 is detailed in Scheme 5. Its precursor
21 was obtained in three steps (reduction, bromination, and
phosphorylation), with 86% overall yield, starting from the
commercially available dimethyl-5-hydroxyisophthalate. Amine
22 was then easily prepared from 21 by Williamson etherification
in the presence of Boc-2-bromoethylamine followed by the treat-
ment with TFA (67% over 2 steps).
Synthesis of bis-amino bis-ethylphosphonate tweezers.
Bis-ethyl phosphonate 26 was obtained following the synthetic
route depicted in Scheme 6. Synthesis of the carboxylic acid
intermediate 24 was accomplished in two steps starting from
3,5-dihydroxybenzoic acid methyl ester: etherification in acetone
with Boc-2-bromoethylamine under basic conditions (23) (65%)
followed by saponification by sodium hydroxide (NaOH) (86%).
A peptide coupling between amine 22 and acid 24 in the
Scheme 2 Synthesis of mono-ethylphosphonate anchor 12. (a) TsCl,
NaOH, THF/H2O, rt, 24 h, 94%; (b) benzyl bromide, KHCO3, KI, DMF,
30 1C, 4 d, 70%; (c) K2CO3, KI, acetone, reflux, 24 h, 75%; (d) NaOH, MeOH/
H2O, reflux, 2 h, 90%; (e) LiAlH4 1 M in THF, THF, rt, 1 h, 90%; (f) SOCl2,
CH2Cl2, reflux, 2 h, 70%; (g) P(OEt)3, 160 1C, 3 h, 85%; (h) Pd/C 10%,
H2, EtOH, rt, 16 h, 96%.
Scheme 3 Synthesis of mono-ethylphosphonate anchor 15. (a) P(OEt)3,
160 1C, 3 h, 92%; (b) Pd/C 10%, H2, EtOH, rt, 16 h, 92%; (c) Boc-2-
bromoethylamine, K2CO3, KI, acetone, reflux, 16 h; (d) TFA, CH2Cl2, 0 1C to
rt, 16 h, 94%.
Scheme 4 Synthesis of mono-ethylphosphonate anchor 18. (a) CBr4,
PPh3, THF, 0 1C at rt, 2 h, 88%; (b) P(OEt)3, 160 1C, 2 h, 75%; (c) Boc-2-
bromoethylamine, K2CO3, KI, acetone, reflux, 16 h, 65%; (d) TFA, CH2Cl2,
0 1C to rt, 16 h, 95%.
Scheme 5 Synthesis of bis-ethylphosphonate anchor 22. (a) LiAlH4 1 M in
THF, THF, reflux, 3 h, 94%; (b) HBr in acetic acid 30%, acetic acid, rt, 24 h,
96%; (c) P(OEt)3, 160 1C, 2 h, 95%; (d) Boc-2-bromoethylamine, K2CO3, KI,
acetone, reflux, 16 h, 76%; (e) TFA, CH2Cl2, 0 1C to rt, 16 h, 88%.
Scheme 6 Synthesis of bis-ethylphosphonate anchor 26. (a) Boc-2-
bromoethylamine, K2CO3, KI, acetone, reflux, 16 h, 65%; (b) NaOH,
MeOH/H2O, reflux, 2 h, 86%; (c) 22, BOP, DIPEA, CH2Cl2, rt, 24 h, 65%;
(d) TFA, CH2Cl2, 0 1C to rt, 16 h, 98%.
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presence of (benzotriazol-1-yloxy)tris(dimethylamino)phos-
phonium hexafluorophosphate (BOP) and N,N-diisopropyl-
ethylamine (DIPEA) led to 25 with 65% yield. Finally, Boc
removal by TFA yielded 26 as a di-trifluoroacetate salt (98%).
Synthesis of dendritic mono- and bis-ethylphosphonates.
The synthetic route to phenolic intermediates 28, 30, 32, 34 is
described in Scheme 7. Amines 15, 18, 22 or 26 underwent a
peptide coupling type reaction with carboxylic acid 8 (obtained
by saponification of 7 with NaOH, Scheme 2) in the presence of
BOP and DIPEA to obtain benzylated compounds 27, 29, 31
or 33 (70–85%) respectively. Finally, hydrogenolysis in the
presence of Pd/C led to the corresponding ethyl phosphonates
28, 30, 32 or 34, respectively, with 75 to 85% yield.
Synthesis of COOH-functionalized dendritic phosphonic
acids. Refluxing in concentrated hydrochloric acid (HCl) is an
easy route for conversion of phosphonate esters into their acid
analogues. However, for sensitive products requiring milder
reaction conditions, McKenna’s method28 using bromotri-
methylsilane (TMSBr) remains an eﬃcient method which
allows the obtention of trimethylsilyl phosphonate ester inter-
mediates that hydrolyze in situ into phosphonic acids, in protic
medium (water or alcohol).
In order to achieve the synthesis of phosphonic acids 40–43
bearing a long functionalized oligoethylene glycol chain in the para
position, the first step was the synthesis of the common inter-
mediate 35 (Scheme 8), which was obtained in good yield starting
from the commercially available hydroxy-dPEGs8-t-butylester.
29
35 then underwent aWilliamson reaction with ethylphosphonates
28, 30, 32 or 34 in acetone at 60 1C in the presence of K2CO3 and
KI to yield the corresponding dendritic ethyl phosphonates 36–39
in 70–90% yield. Treatment of 36, 37, 38 or 39 with a large excess
of TMSBr generated a phosphonic acid function at the focal point
and converted the terminal tert-butyl ester group into its corre-
sponding carboxylic acid. This step allowed the obtention of
compounds 40–43 in 85–95% yields.
Synthesis of dye-functionalized dendritic phosphonic acids
via click chemistry. Phenols 12 and 28, 30, 32, 34 were sub-
jected to an etherification reaction in acetone at reflux in the
presence of propargyl bromide (Scheme 9).
The corresponding acetylenic derivatives 44–48 were engaged
in click reactions with azide-derivatized Patent Blue VF Dye
(Scheme 10).
Patent Blue VF was first converted into sulfonyl chloride 49
by treatment with phosphoryl chloride (POCl3) for 3 days and
was used without further purification. The reaction between the
commercially available OEGylated azide and sulfonyl chloride
49 led to the preparation of sulfonamide 50 in a moderate 50%
yield. The click reaction between propargyl derivatives 44–48,
and 50, in the presence of copper(II) sulphate (CuSO45H2O)
and sodium ascorbate, gave ethyl phosphonates 51, 53, 55, 57,
59 in 50–85% yields, which were then deprotected with an
excess of TMSBr to yield their phosphonic acid derivatives 52,
54, 56, 58, and 60 (90–95% yield).
Part II: PAMAM-OEG dendrons
Another design of our small-size dendrons was based on a
small poly(amido)amine structure. Precisely, alkyne monomer
Scheme 7 Synthesis of dendritic ethylphosphonates 28–34. (a) 8, BOP,
DIPEA, CH2Cl2, rt, 24 h, (70–85%); (b) Pd/C 10%, H2, EtOH, rt, 16 h, (75–85%).
Scheme 8 Synthesis of dendritic and functional phosphonic acids
40–43. (a) TsCl, NEt3, CH2Cl2, rt, 24 h, (85%); (b) 35, K2CO3, KI, acetone,
reflux, 16 h, (70–90%); (c) TMSBr, CH2Cl2, rt, 16 h, (85–95%).
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61 was synthesized following a reported procedure (Scheme 11).30
After deprotection of the two methyl esters by sodium trimethyl-
silanolate (TMSONa), functionalized OEG chains (62 or 64) were
introduced into the monomer by a peptide coupling reaction as
shown in Scheme 11 to yield bifunctional acetylenic conjugates (63
or 65). The OEG chains were chosen for their tunable length and
possible derivatization.
In parallel, two azide-derivatized ethylphosphonate pre-
cursors displaying one (67) or two (72) phosphorus anchors
were synthetized (Scheme 12). The mono-ethylphosphonate
precursor 67 was obtained in a two-step sequence starting from
commercially available 1,4-bis(chloromethyl)benzene whereas
the bis-ethylphosphonate anchor 72 was obtained in a four-step
procedure starting from methyl-3,5-dibromomethylbenzoate
68 22c,30,31 (Scheme 12).
Acetylenic PAMAM monomers 63 and 65 underwent the
click reaction catalyzed by Cu(II)SO45H2O in the presence of
sodium ascorbate as the reducing agent with either azide 67 or
72 (Scheme 13) to yield mono-(73) or bis-ethylphosphonates 74
and 75.
Part III: linear phosphonates
Linear aromatic bis-ethyl phosphonates were successfully
prepared via the click reaction (Schemes 14 and 15).32 Discrete
short (76) or long (78)33 alkyne-derivatized OEG arms were
obtained quantitatively starting from their alcohol counterparts
in the presence of propargylbromide and potassium tert-butoxide
(tBuOK) in THF. They were then reacted with azide 72 following
the same procedure described for 74–75 (Scheme 13) to yield
linear bis-ethyl phosphonates 79 and 80, respectively (Scheme 14).
Scheme 9 Synthesis of acetylenic derivatives 44 to 48. (a) Propargyl
bromide in xylene 80%, K2CO3, KI, acetone, reflux, 2 h, (80–90%).
Scheme 10 Synthetic route to dye-functionalized dendritic phosphonic
acids 52, 54, 56, 58 and 60. (a) Patent Blue VF, POCl3, rt, 3 d, 90%;
(b) azido-dPEGt7-amine, NEt3, 4-DMAP, CH2Cl2/DMF, 0 1C to rt, 16 h,
50%; (c) 44, 45, 46, 47 or 48, CuSO45H2O, sodium ascorbate, DMSO/
H2O, rt, 16 h, (50–85%); (d) TMSBr, CH2Cl2, rt, 16 h, (90–95%).
Scheme 11 Introduction of functional OEG chains into a poly(amido)-
amine monomer.22c (a) TMSONa 1 M, CH2Cl2, rt, 16 h, quant; (b) N,N0-
diisopropylcarbodiimide (DIC), hydroxybenzotriazole (HOBt), DMF, 60 1C,
24 h, 70%; (c) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI),
HOBt, DIPEA, CH3CN, rt, 16 h, 67%.
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Functionalized and linear bis-ethyl phosphonates 86 and 87
were similarly (via click reaction) prepared starting from the
azide-OEG arm 84 and 85 and the alkyne-derivatized aromatic
bis-ethyl phosphonate 81 (Scheme 15).
Activated alcohols 82 and 83 34 were quantitatively trans-
formed into their azide derivatives 84 and 85 respectively via a
nucleophilic substitution in the presence of sodium azide
(NaN3) in acetone, under reflux. In parallel, phenol 21 reacted
with propargylbromide under basic conditions to obtain
Scheme 12 Synthesis of mono- and bis-ethylphosphonate azide precur-
sors 67 and 72. For precursor 67: (a) P(OEt)3, 120 1C, 2 h, 48%; (b) NaN3,
CH3CN, reflux, 16 h, 95%. For precursor 72: (a) DIBALH, toluene, 3 h, 0 1C,
90%; (b) P(OEt)3, 2 h, 140 1C, quant; (c) SOCl2, CHCl3, 1 h, reflux, quant;
(d) NaN3, CH3CN, reflux, 16 h, quant.
Scheme 13 Coupling between PAMAMmonomers 63 or 65 and mono or
bisphosphonate precursors 67 and 72 via click reaction. (a) CuSO45H2O/
sodium ascorbate, THF/H2O (4 : 1), rt, 16 h (73: 60%, 74: 75%, 75: 62%).
Scheme 14 Synthesis of linear bis-ethylphosphonates 79 and 80.
(a) TsO-PEG3-Me,
25 KOH, THF, reflux, 18 h, 65%; (b) propargylbromide,
tBuOK, THF, rt, 1 week; (c) 72, CuSO45H2O/sodium ascorbate, THF/H2O
(4 : 1), rt, 16 h (79: 65%, 80: 61%).
Scheme 15 Synthesis of functional bis-ethylphosphonates 86 and 87.
(a) Propargylbromide, K2CO3, 18-crown-6, acetone, reflux, 16 h, 84%;
(b) NaN3, acetone, reflux, 16 h (84 see ref. 30, 85: quant); (c) 72, CuSO4
5H2O/sodium ascorbate, THF/H2O (4 : 1), rt, 16 h (86: 32%, 87: 69%).
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alkyne-derivatized bisphosphonate 81 which underwent the Cu(II)
catalyzed Huisgen 1,3-dipolar cycloaddition in the presence of 84
or 85 and sodium ascorbate as the reducing agent, to obtain 86
(34%) and 87 (71%), respectively, in moderate yields.
Aliphatic and hydrophilic monophosphonates were pre-
pared in a two-step sequence starting from the activated
alcohols 82 and 83 (Scheme 16). Once transformed into their
corresponding halides 88 and 89, respectively, they underwent
the second step of the Michaelis–Arbuzov reaction in the
presence of P(OEt)3 to obtain ethylphosphonates 90 and 91
quantitatively.
The final deprotection of the previously mentioned mono- or
bis-ethylphosphonates (Schemes 13–16) was achieved in the
presence of TMSBr, which allowed the simultaneous deprotec-
tion of tert-butyl esters of compounds 73, 74, 86, 87, 90 and 91,
whereas a two-step sequence was necessary to yield hydroxy-
functionalized bis-phosphonic acid 92 (Scheme 17).
Proof of concept of dendronized iron oxide nanoparticles.
Designing and synthesizing hybrid materials is of utmost
importance since such materials can display strong versatility
and adaptability in biomedical applications due to an appro-
priate organic coating. Aqueous suspensions of dendronized
iron oxide nanoparticles (NPs), synthesized by co-precipitation
(leading to naked NPs in water) or by thermal decomposition
(NPs in situ coated by oleic acid in an organic solvent), have
been obtained after functionalization of NPs with either phos-
phonic acid 1, 2, 3,21a,c,22b,25,26a 4, 58, 60,26b 92,22c 93 21c or 94 22c
(Fig. 2). Diﬀerent grafting strategies have been optimized
depending on the NPs synthetic method.21a,24a,b The size distri-
bution, the colloidal stability in isoosmolar media (Fig. 3), the
surface complex nature as well as the preliminary biokinetic
studies performed with optical imaging, and the contrast
enhancement properties evaluated through in vitro and
in vivo MRI experiments, have been compared as a function
of the nature of both organic shell and NPs.22a–c,25,26a,b All
functionalized NPs displayed good colloidal stability in water;
however, the ones bearing a peripheral carboxylic acid function
gave the best results in iso-osmolar media.22
Whereas the grafting rates were similar, the nature of the
surface complex depended on the NPs synthetic method. The
in vitro contrast enhancement properties were better than
commercial products (Table 1), with a better performance of the
NPs synthesized by co-precipitation.25 On the other hand, the NPs
synthesized by thermal decomposition were more eﬃcient in vivo.
However, all of our previously reported studies21,22,24–26 clearly
highlighted that the dendritic organic coating impacts the
nanoobject aggregation state, thus influencing the bioelimination
speed and importance of the hepato-biliary versus urinary
Scheme 16 Synthesis of linear and functional mono-ethylphosphonates
90 and 91. (a) LiBr, acetone, reflux, 16 h (88: 72%, 89: 70%); (b) P(OEt)3,
reflux, 2 h (90: quant, 91: 92%).
Scheme 17 Final deprotection step of functional dendritic and linear
mono- and bis-ethyl phosphonates. (a) TBAF, THF, rt, 16 h; (b) TMSBr,
CH2Cl2, rt, 2–4 h (92: 75%, 93: 98%, 94: 91%, 95: 98%, 96: 99%, 97: 98%,
98: 97%, 99: 83%, 100: 99%).
Fig. 2 TEM images of dendronized iron oxides NPs@94 of 10 nm.22c
Fig. 3 Evolution of the size distribution of NP@94 (’) and NP@94 diluted
(&) in sodium chloride medium (0.15 M NaCl) after 24 h.22c
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elimination pathway: NPs covered with small dendrons are more
rapidly and completely eliminated within 24 hours post intrave-
nous injection, predominantly by urinary elimination.
Conclusions
The chemistry of phosphonates and related multifunctional
hybrids has witnessed an exponential growth, due to the
potential applications of these compounds in medicine and
nanobiomaterial research. A variety of discretely sized hydro-
philic dendritic or linear phosphonic acids useful for the
functionalization of metal oxide nanoparticles have been
synthesized with high yields. A number of them were success-
fully grafted onto iron or manganese oxide nanoparticles
through a ligand exchange method to aﬀord stable and bio-
compatible nano-colloids, the bioelimination of which was
mainly renal. This library of phosphonates may stimulate the
development of advanced hybrid materials for better in vivo
performance and sensitivity.
Experimental
General
All reactions were performed under an argon atmosphere.
All the solvents, dichloromethane (CH2Cl2), tetrahydrofurane
(THF), acetonitrile (CH3CN), toluene, acetone, ethanol (EtOH),
methanol (MeOH), chloroform (CHCl3), dimethylformamide
(DMF), ethyl acetate (EtOAc), and cyclohexane (CH), were of
HPLC grade (chromasolvs, Sigma-Aldrich) further purified in a
solvent system containing drying columns or dried over 4 Å
molecular sieves. All commercially available reagents were used
without further purification. Flash column chromatography
was performed on silica gel (high-purity grade, 230–400 mesh,
40–63 mm, Sigma-Aldrich) according to a standard technique.
Nuclear magnetic resonance spectra (1H, 13C and 31P) were
recorded on a Bruker spectrometer (300 MHz). Chemical shifts
for 1H and 13C spectra are recorded in parts per million and are
calibrated to solvent residual peaks (for example: CHCl3:
1H
7.26 ppm, 13C 77.16 ppm; MeOH: 1H 3.31 ppm, 13C 49.00 ppm)
according to ref. 35. Multiplicities are indicated by s (singlet),
bs (broad singlet), d (doublet), t (triplet), q (quadruplet),
quint (quintuplet) and m (multiplet). Coupling constants, J,
are reported in Hertz. Exact mass was obtained through Matrix
Assisted Laser Desorption Ionization Time Of Flight mass
spectrometry (MALDI-TOF MS).
The experimental section is composed of the syntheses
of phosphonated anchors and final compounds. All the other
syntheses are described in the ESI† (1H, 13C, 31P, Maldi-TOF,
see ESI†).
Part I: amino or hydroxy-bearing mono- or bi-phosphonates
Compound 12. Palladium activated on carbon 10% (0.4 g,
0.75 mmol) was added to a solution of 11 (2.0 g, 2.6 mmol)
dissolved in ethanol (30 mL). The mixture was stirred under a
hydrogen atmosphere at room temperature for 16 h. The
product was filtered through a plug of Celite before being
concentrated and purified by column chromatography (SiO2,
CH2Cl2/MeOH 95 : 5) to aﬀord 12 (2.5 mmol, 96%). Pale yellow
oil. Spectroscopic data of 12 have already been reported in the
literature.29
Compound 15. (2-Bromo-ethyl) carbamic acid tert-butyl ester
(1.4 g, 6.3 mmol, 3 equiv.), K2CO3 (0.87 g, 6.3 mmol, 3 equiv.)
and KI (0.05 g, 0.4 mmol, 0.2 equiv.) were added to a solution of
14 (0.5 g, 2.1 mmol) in acetone (25 mL). The mixture was stirred
for 72 h at 65 1C, filtered over Celite and concentrated under
reduced pressure. The resulting crude product was diluted in
CH2Cl2 (50 mL) and washed twice with an aqueous saturated
solution of NaHCO3 and with brine. After drying over MgSO4,
filtration and evaporation of the solvent, the crude product was
purified by column chromatography (SiO2, CH2Cl2/MeOH 95/5)
to aﬀord the protected amine as yellow oil in 63% yield.
Trifluoroacetic acid (1.1 mL, 13 mmol, 10.0 equiv.) was added
dropwise at 0 1C to a solution of Boc-protected amine (0.5 g,
1.3 mmol) in CH2Cl2 (15 mL). The reaction mixture was stirred
overnight at room temperature, and then the volatiles were
evaporated. The crude product was dissolved in a mixture of
CH2Cl2/MeOH (9/1) (20 mL) and was washed with NaOH 1 N
(2 10 mL). The organic layer was dried over MgSO4, filtered and
concentrated under reduced pressure to aﬀord 15 (1.97 mmol,
94%), which was used without further purification. White foam.
1H NMR (300 MHz, CD3OD) d 7.20 (dd, J = 2.7 and 8.0 Hz, 2H,
Ar-2,6-H), 6.85 (d, J = 8.0 Hz 2H, Ar-3,5-H), 4.02 (m, 6H,
OCH2CH2NH and PO(OCH2CH3)2), 3.08 (m, 4H, OCH2CH2NH
and Ar1CH2P), 1.21 (t, J = 7.0 Hz, 6H, PO(OCH2CH3)2);
13C NMR
(75 MHz, CD3OD) d 157.8 ( J = 3.3 Hz) (Ar), 130.7 ( J = 6.6 Hz) (Ar),
123.6 ( J = 9.3 Hz) (Ar), 114.6 ( J = 2.7 Hz) (Ar), 70.0 (OCH2), 62.0
( J = 6.6 Hz) (CH2CH3), 41.4 (CH2NH2), 32.5 ( J = 138.9 Hz) (CH-P),
16.3 ( J = 6.1 Hz) (CH2CH3);
31P NMR (81 MHz, CD3OD) d 26.81.
MS (MALDI-TOF) m/z calculated for C13H23NO4P: 288.13,
obtained: 288.19.
Compound 18. (2-Bromo-ethyl)carbamic acid tert-butyl ester
(3.1 g, 13.9 mmol, 2.4 equiv.), K2CO3 (4.8 g, 34.6 mmol, 6 equiv.)
and KI (0.2 g, 1.1 mmol, 0.2 equiv.) were added to a solution of
17 (1.5 g, 5.8 mmol) in acetone (120 mL). The mixture was
stirred for 72 h at 65 1C, filtered over Celite and evaporated
Table 1 In vitro relaxivity studies (1.5 T, room temperature) of dendronized nanoparticles compared to commercially available polymer-coated
nanoparticles
Compound (company) Coating agent DH (nm) r1 (mM
1 s1) r2 (mM1 s1) r2/r1
Sinerem (Guerbet) Dextran 51–30 9.9 65 6.7
NP@1 Dendritic-OEG monophosphonate 30  1.5 6.2 91.2 14.7
NP@94 Dendritic-PAMAM bisphosphonate 30  1.5 7.7 53.8 7.0
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under reduced pressure. The resulting crude product was
diluted in CH2Cl2 (100 mL) and washed twice with an aqueous
saturated solution of NaHCO3 and with brine. After drying over
MgSO4, filtration and evaporation of the solvent, the crude
product was purified by chromatography (SiO2, CH2Cl2/MeOH
100 to 98/2) to aﬀord the protected diamine as yellow oil in 65%
yield. 2.4 mL of trifluoroacetic acid (27.4 mmol, 20.0 equiv.) was
then added dropwise to a solution of protected diamine (0.75 g,
1.4 mmol) in CH2Cl2 (35 mL) at 0 1C. The reaction mixture
was stirred overnight at room temperature, and then the
volatiles were evaporated. Compound 18 was obtained as a salt
(1.3 mmol, 95%) and was used without further purification.
White foam. 1H NMR (300 MHz, CD3OD) d 6.55 (t, J = 2.3 Hz,
2H, Ar-2,4-H), 6.42 (m, 1H, Ar-6-H), 4.11 (t, J = 5.0 Hz, 4H,
OCH2CH2NH), 3.98–3.87 (m, 4H, PO(OCH2CH3)2), 3.23–3.20
(m, 4H, OCH2CH2NH2), 3.11 (d, J = 21.8 Hz, 2H, ArCH2P),
1.18 (t, J = 7.0 Hz, 6H, PO(OCH2CH3)2);
13C NMR (75 MHz,
CD3OD) d 158.8 ( J = 2.6 Hz) (Ar), 133.5 ( J = 8.8 Hz) (Ar), 108.7
( J = 6.6 Hz) (Ar), 99.6 ( J = 3.3 Hz) (Ar), 63.5 (OCH2), 61.9 ( J = 7.1 Hz)
(CH2CH3), 38.2 (CH2NH2), 31.8 ( J = 137.8 Hz) (CH-P), 14.8 ( J = 6.0
Hz) (CH2CH3);
31P NMR (81 MHz, CD3OD) d 27.24. MS (MALDI-
TOF) m/z calculated for C15H27NaN2O13P: 369.17, obtained: 369.12;
calculated for C15H27Na2N2O13P: 392.17, obtained: 392.15.
Compound 22. (2-Bromo-ethyl)carbamic acid tert-butyl ester
(1.1 g, 4.95 mmol, 1.3 equiv.), K2CO3 (2.1 g, 15.2 mmol, 4 equiv.)
and KI (0.1 g, 0.4 mmol, 0.1 equiv.) were added to a solution of
21 (1.5 g, 3.8 mmol) in acetone (40 mL). The mixture was stirred
for 48 h at 65 1C, filtered over Celite and evaporated under
reduced pressure. The resulting crude product was diluted in
CH2Cl2 (100 mL) and washed twice with an aqueous saturated
solution of NaHCO3 and with brine. After drying over MgSO4,
filtration and evaporation of the solvent, the crude product was
purified by column chromatography (SiO2, CH2Cl2/MeOH 98/2
to 95/5) to aﬀord the (Boc-amino) derivative as a white solid
(76%). The compound (1.2 g, 2.2 mmol) was then dissolved in
anhydrous CH2Cl2 (30 mL) at 0 1C and trifluoroacetic acid
(2 mL, 22.0 mmol, 10.0 equiv.) was added dropwise. The
reaction mixture was stirred overnight at room temperature,
and then the volatiles were evaporated. The crude product was
dissolved in CH2Cl2 (20 mL) and was washed with NaOH 1 N
(2  10 mL). The organic layer was dried over MgSO4, filtered
and concentrated under reduced pressure to aﬀord 21 (1.9mmol,
88%) as a white foam, which was used without further purifica-
tion. 1H NMR (300 MHz, CDCl3) d 6.72 (m, 3H, Ar-2,4,6-H), 5.25
(br s, 2H, OCH2CH2NH2), 4.03–3.92 (m, 10H, PO(OCH2CH3)2 and
OCH2CH2NH), 3.10 (d, J = 21.7 Hz, 4H, ArCH2P), 3.02 (m, 2H,
OCH2CH2NH), 1.25 (t, J = 7.1 Hz, 12H, PO(OCH2CH3)2);
13C NMR
(75 MHz, CDCl3) d 159.0 ( J = 2.8 Hz) (Ar), 133.1 ( J = 6.0 Hz) (Ar),
123.8 ( J = 6.8 Hz) (Ar), 114.5 ( J = 5.0 Hz) (Ar), 70.0 (OCH2), 62.1
( J = 7.0 Hz) (CH2CH3), 41.5 (CH2NH2), 33.5 ( J = 138.2 Hz) (CH-P),
16.5 ( J = 2.7 Hz) (CH2CH3);
31P NMR (81 MHz, CDCl3) d 26.24. MS
(MALDI-TOF) m/z calculated for C18H34NO7P2: 438.17, obtained:
438.18; calculated for C18H34NaO7P2: 460.17, obtained: 460.16.
Compound 26. Trifluoroacetic acid (780 mL, 8.0 mmol) was
added dropwise to a solution of 25 (0.4 g, 0.4 mmol) in CH2Cl
2
(15 mL) at 0 1C. The reaction mixture was stirred overnight at
room temperature, and then the volatiles were evaporated. The
compound 26 was obtained as a salt (0.39 mmol, 98%) and
was used without further purification. White foam. 1H NMR
(300 MHz, CD3OD) d 8.74 (m, 1H, Ar1OCH2CH2NH), 8.55
(m, 4H, Ar2OCH2CH2NH2), 6.95 (m, 2H, Ar
1-2,6-H), 6.85–6.78
(m, 3H, Ar2-2,4,6-H), 6.69 (m, 1H, Ar1-4-H), 4.21 (m, 2H,
Ar1OCH2CH2NH), 4.05–3.90 (m, 12H, Ar
2OCH2CH2NH and
PO(OCH2CH3)2), 3.78 (m, 2H, Ar
1OCH2CH2NH), 3.58–3.50
(m, 4H, Ar2OCH2CH2NH), 3.08 (d, J = 22.0 Hz, 4H, Ar
1CH2P),
1.25 (t, J = 7.0 Hz, 12H, PO(OCH2CH3)2);
13C NMR (75 MHz,
CD3OD) d 167.8 (CONH), 158.7 (Ar), 136.2 (Ar), 132.5 (Ar), 123.3
(Ar), 114.1 ( J = 4.9 Hz) (Ar), 105.8 (Ar), 104.4 (Ar), 65.6 (OCH2-
CH2NH), 63.8 (OCH2CH2NH2), 61.9 ( J = 3.3 Hz) (CH2CH3), 38.8
(CH2NHCOAr), 38.2 (CH2NH2), 31.4 ( J = 147.8 Hz) (CH-P), 14.8
( J = 2.7 Hz) (CH2CH3);
31P NMR (81 MHz, CD3OD) d 27.41. MS
(MALDI-TOF) m/z calculated for C29H48N3O14P2: 660.27,
obtained: 660.24; calculated for C29H48NaN3O14P2: 682.27,
obtained: 682.22.
General procedure for the conversion of phosphonate ester to
phosphonic acid by TMSBr (McKenna’s method28) (40–43)
TMSBr (10.0 equiv. per ethyl phosphonate and tert-butyl ester
function) was added dropwise to a solution of ethyl phospho-
nate (36–39) in CH2Cl2 at 0 1C. After stirring overnight at room
temperature, the volatiles were evaporated and MeOH was
added to the crude product, and then evaporated. The phos-
phonic acid was obtained without further purification.
Compound 40. Starting from 36 (0.13 g, 0.10 mmol) and
TMSBr (0.26 mL, 2 mmol, 20 equiv.), 40 was obtained
(0.09 mmol, 93%) as an orange oil. 1H NMR (300 MHz, CD3OD)
d 7.307.25 (m, 4H, Ar1-2,6-H and Ar2-2,6-H), 6.97 (d, J = 8.3 Hz,
2H, Ar1-3,5-H), 4.31–4.18 (m, 8H, Ar1OCH2CH2NH and Ar
2OCH2-
CH2O), 3.93 (m, 6H, OCH2CH2O), 3.85–3.50 (m, 56H, OCH2-
CH2O), 3.41 (s, 6H, OCH2CH2OCH3), 3.12 (d, J = 21.3 Hz, 2H,
Ar1CH2P), 2.63 (t, 2H, J = 6.1 Hz, Ar
2OCH2CH2COOH);
13C NMR
(75 MHz, CD3OD) d 171.8 (COOH), 167.8 (NHCO), 157.2 (Ar),
151.8 (Ar), 140.4 (Ar), 130.1 ( J = 6.0 Hz) (Ar), 128.5 (Ar), 124.3
( J = 9.3 Hz) (Ar), 113.8 (Ar), 106.1 (Ar), 71.8 (PEG), 71.0 (PEG), 69.9
(PEG), 69.8 (PEG), 69.7 (PEG), 69.6 (PEG), 69.4 (PEG), 69.3 (PEG),
68.9 (PEG), 68.2 (PEG), 65.8 (OCH2CH2NH), 65.6 (CH2CH2COO),
57.2 (OCH3), 50.1, 39.0 (CH2NHCOAr), 33.9 (CH2COO), 32.8
( J = 135.5 Hz) (CH-P); 31P NMR (81 MHz, CD3OD) d 25.32. MS
(MALDI-TOF)m/z calculated for C53H90NaNO26P: 1210.55 obtained:
1220.57; calculated for C61H106KNO26P: 1226.55, obtained: 1226.58.
Compound 41. Starting from 37 (0.1 g, 0.04 mmol) and
TMSBr (0.16 mL, 1.2 mmol, 30 equiv.), 41 was obtained
(0.034 mmol, 86%) as an orange oil. 1H NMR (300 MHz,
CD3OD) d 7.28 (s, 4H, Ar
2-2,6-H), 6.62 (t, 2H, J = 2.0 Hz, Ar1-
2,6-H), 6.51 (t, J = 2.0 Hz, 1H, Ar1-4-H), 4.30–4.25 (m, J = 4.3 Hz,
12H, Ar2OCH2CH2O), 4.20 (t, 4H, J = 5.3 Hz, Ar
1OCH2CH2NH),
3.95–3.75 (m, 16H, Ar1OCH2CH2NH and OCH2CH2O), 3.80–3.55
(m, 108H, OCH2CH2O), 3.41 (s, 12H, OCH2CH2OCH3), 3.12
(d, J = 21.4 Hz, 2H, Ar1CH2P), 2.62 (t, 4H, J = 6.6 Hz, Ar
2OCH2CH2-
COOH); 13C NMR (75 MHz, CD3OD) d 172.2 (COOH), 168.2
(NHCO), 159.8 ( J = 3.3 Hz) (Ar), 152.2 (Ar), 141.1 (Ar), 129.2
(Ar), 108.7 ( J = 6.6 Hz) (Ar), 106.4 (Ar), 72.2 (PEG), 71.6 (PEG),
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70.3 (PEG), 70.2 v, 70.1 (PEG), 70.0 (PEG), 70.3 (PEG), 69.9 (PEG),
69.5 (PEG), 68.7 (PEG), 66.3 (OCH2CH2NH), 66.1 (CH2CH2COO),
57.8 (OCH3), 50.8, 39.5 (CH2NHCOAr), 33.8 (CH2COO), 32.6
( J = 133.4 Hz) (CH-P); 31P NMR (81 MHz, CD3OD) d 24.22. MS
(MALDI-TOF) m/z calculated for C99H171NaN2O49P: 2223.07
obtained: 2223.09.
Compound 42. Starting from 38 (0.2 g, 0.14 mmol) and
TMSBr (0.55 mL, 3 mmol, 30 equiv.), 42 was obtained
(0.13 mmol, 94%) as an orange oil. 1H NMR (300 MHz, CD3OD)
d 7.28 (s, 2H, Ar2-2,6-H), 6.92–6.86 (m, 3H, Ar1-2,4,6-H), 4.35–
4.20 (m, 8H, Ar2OCH2CH2O and Ar
1OCH2CH2NH), 3.92–3.82
(m, 8H, Ar1OCH2CH2NH and OCH2CH2O), 3.80–3.53 (m, 54H,
OCH2CH2O), 3.38 (s, 6H, OCH2CH2OCH3), 3.18 (d, J = 21.8 Hz,
4H, Ar1CH2P), 2.62 (t, 2H, J = 6.0 Hz, Ar
2OCH2CH2COOH);
13C
NMR (75 MHz, CD3OD) d 172.2 (COOH), 167.1 (NHCO), 158.8
(Ar), 152.3 (Ar), 141.0 (Ar), 134.8 ( J = 6.0 Hz) (Ar), 128.8 (Ar),
123.8 (Ar), 114.3 (Ar), 106.4 (Ar), 72.2 (PEG), 71.7 (PEG), 70.4
(PEG), 70.25 (PEG), 70.15 (PEG), 70.1 (PEG), 70.0 (PEG), 69.95
(PEG), 69.4 (PEG), 68.8 (PEG), 66.3 (OCH2CH2NH), 66.1
(CH2CH2COO), 57.8 (OCH3), 50.8, 39.6 (CH2NHCOAr), 34.6
(CH2COO), 33.6 ( J = 134.5 Hz) (CH-P);
31P NMR (81 MHz,
CD3OD) d 25.19. MS (MALDI-TOF) m/z calculated for
C54H94NO29P2: 1282.53, obtained: 1282.46; calculated for
C54H93NaNO29P2: 1304.53, obtained: 1304.45.
Compound 43. Starting from 39 (0.08 g, 0.03 mmol) and
TMSBr (0.16 mL, 1.2 mmol, 40 equiv.), 43 was obtained
(0.028 mmol, 93%) as an orange oil. 1H NMR (300 MHz, CD3OD)
d 7.27 (s, 4H, Ar3-2,6-H and Ar2-4-H), 7.11 (d, J = 1.7 Hz, 2H, Ar2-2,6-
H), 6.90–6.85 (m, 3H, Ar1-2,4,6-H), 6.82 (m, 1H, Ar2-4-H), 4.30–4.18
(m, 18H, Ar1OCH2CH2NH, Ar
2OCH2CH2NH and Ar
3OCH2CH2O),
3.95–3.83 (m, 18H, Ar1OCH2CH2NH, Ar
2OCH2CH2NH and OCH2-
CH2O), 3.80–3.53 (m, 108H, OCH2CH2O), 3.38 (s, 12H, OCH2-
CH2OCH3), 3.12 (d, J = 21.6 Hz, 4H, Ar
1CH2P), 2.63 (t, 4H,
J = 6.6 Hz, Ar3OCH2CH2COOH);
13C NMR (75 MHz, CD3OD) d
172.1 (COOH), 168.2 (NHCO), 159.9 (Ar), 158.8 (Ar), 152.2 (Ar),
140.8 (Ar), 136.2 (Ar), 134.3 (Ar), 129.0 (Ar), 114.3 (Ar), 106.5 (Ar),
105.8 (Ar), 104.5 (Ar), 72.2 (PEG), 71.5 (PEG), 70.3 (PEG), 70.2
(PEG), 70.1 (PEG), 70.0 (PEG), 69.95 (PEG), 69.9 (PEG), 69.4 (PEG),
68.6 (PEG), 66.2 (OCH2CH2NH), 65.8 (CH2CH2COO), 57.8 (OCH3),
50.8, 39.4 (CH2NHCOAr), 34.5 (CH2COO), 34.1 ( J = 136.2 Hz)
(CH-P); 31P NMR (81 MHz, CD3OD) d 24.03. MS (MALDI-TOF) m/z
calculated for C79H127N3O34P2: 1723.78, obtained: 1723.46; calcu-
lated for C29H53NaO14P: 679.31, obtained: 679.24.
General procedure for the conversion of phosphonate ester to
phosphonic acid by TMSBr (McKenna’s method28) (52, 54, 56,
58, and 60)
TMSBr (10.0 equiv. per ethyl phosphonate) was added dropwise
to a solution of ethyl phosphonate (51, 53, 55, 57, 59) in CH2Cl2
at 0 1C. After stirring overnight at room temperature, the
volatiles were evaporated and MeOH was added to the crude
product and then evaporated several times. The phosphonic
acid was obtained without further purification.
Compound 52. Starting from 51 (0.12 g, 0.07 mmol), 52 was
obtained (0.06 mmol, 90%) as a dark yellow-green foam without
further purification. 1H NMR (300 MHz, CD3OD) d 8.77 (s, 1H,
ArTriazole-H), 8.54 (d, J = 1.9 Hz, 1H, Ardye-2-H), 8.09 (dd, J = 1.7
and 7.9 Hz, 1H, Ardye-6-H), 7.62 (d, 4H, J = 8.2 Hz, Ardye-AA0-H),
7.52 (d, J = 7.8 Hz, 1H, Ardye-5-H), 7.44 (d, 4H, J = 9.4 Hz, Ardye-
BB0-H), 6.68 (d, J = 2.2 Hz, 2H, Ar1-2,6-H), 5.34 (s, 2H, OCH2Ar-
Triazole-CH2), 4.89 (t, J = 4.6 Hz, 2H, OCH2ArTriazole-CH2), 4.18
(t, J = 4.4 Hz, 4H, Ar1OCH2CH2), 4.04 (t, J = 4.6 Hz, 2H, CH2-
CH2NHO2), 3.88–3.80 (m, 12H, OCH2CH2O and N(CH2CH3)2),
3.72–3.50 (m, 50H, OCH2CH2O), 3.32 (s, 6H, OCH2CH2OCH3),
3.18 (t, J = 5.2 Hz, 2H, CH2CH2NHO2), 3.14 (d, J = 22.0 Hz, 2H,
Ar1CH2P), 1.31 (t, J = 7.1 Hz, 12H, N(CH2CH3)2); 13C NMR
(75 MHz, CD3OD) d 158.5 ( J = 3.3 Hz) (Ardye = N), 145.2 (Ar),
142.1 (ArTriazole), 140.6 (Ar), 139.5 (Ar), 139.1 (Ar), 134.2 (Ar),
131.8 (Ar), 129.5 ( J = 8.8 Hz) (Ar), 127.6 (ArTriazole), 127.2 (Ar),
127.1 (Ar), 125.8 (Ar), 116.0 (Ar), 107.8 ( J = 6.6 Hz) (Ar), 71.9
(OCH2-ArTriazole), 71.0 (PEG), 70.7 (PEG), 70.6 (PEG), 70.5
(PEG), 70.4 (PEG), 68.8 (PEG), 68.6 (PEG), 67.5 (OCH2CH2NH),
62.5 (PEG), 60.2 (PEG), 57.2 (OCH3), 52.2 (ArTriazole-CH2), 48.4
(N(CH2CH3)2), 42.1 (CH2NHSO2), 33.9 ( J = 138.5 Hz) (CH-P),
10.8 (N(CH2CH3)2);
31P NMR (81 MHz, CD3OD) d 24.09. MS
(MALDI-TOF) m/z calculated for C71H112N6O26PS2: 1559.67,
obtained: 1559.56; calculated for C71H111NaN6O26PS2:
1581.67, obtained: 1581.55.
Compound 54. Starting from 53 (0.11 g, 0.06 mmol), 54 was
obtained (0.055 mmol, 94%) as a dark yellow-green foam
without further purification. 1H NMR (300 MHz, CD3OD)
d 8.82 (s, 1H, ArTriazole-H), 8.61 (m, 1H, Ardye-2-H), 8.18
(m, 1H, Ardye-6-H), 7.72–7.52 (m, 9H, Ardye-5-H, Ardye-AA0-H
and Ardye-BB0-H), 7.36 (s, 2H, Ar2-2,6-H), 7.28 (d, 2H, J = 7.6 Hz,
Ar1-2,6-H), 6.97 (d, 2H, J = 7.6 Hz, Ar1-3,5-H), 5.49 (s, 2H,
OCH2ArTriazole-CH2), 4.95 (m, 2H, OCH2ArTriazole-CH2), 4.30
(m, 4H, Ar2OCH2CH2), 4.21 (t, 2H, J = 4.7 Hz, Ar
1OCH2CH2NH),
4.08 (t, J = 4.7 Hz, 2H, CH2CH2NHO2), 3.88–3.80 (m, 6H,
OCH2CH2O and Ar
1OCH2CH2NH), 3.82–3.50 (m, 58H, OCH2-
CH2O and N(CH2CH3)2), 3.38 (s, 6H, OCH2CH2OCH3), 3.22
(t, J = 5.2 Hz, 2H, CH2CH2NHO2), 3.20 (d, J = 22.0 Hz, 2H,
Ar1CH2P), 1.38 (t, J = 7.1 Hz, 12H, N(CH2CH3)2);
13C NMR
(75 MHz, CD3OD) d 167.8 (NHCO), 157.9 ( J = 3.3 Hz) (Ar),
152.1 (Ardye = N), 145.2 (Ar), 142.7 (ArTriazole), 140.6 (Ar), 139.5
(Ar), 138.1 (Ar), 130.8 ( J = 8.8 Hz) (Ar), 130.3 (Ar), 128.9 (Ar),
128.1 (ArTriazole), 126.5 (Ar), 124.7 ( J = 9.6 Hz) (Ar), 120.1 (Ar),
114.4 (Ar), 106.1 (Ar), 72.1 (OCH2-ArTriazole), 71.5 (PEG), 70.7
(PEG), 70.6 (PEG), 70.5 (PEG), 70.4 (PEG), 69.4 (PEG), 69.2
(PEG), 68.5 (PEG), 67.8 (PEG), 66.1 (OCH2CH2NH), 62.5 (PEG),
60.8 (PEG), 57.8 (OCH3), 53.2 (ArTriazole-CH2), 48.6 (N(CH2-
CH3)2), 42.8 (CH2NHSO2), 39.4 (CH2NHCOAr), 32.9 ( J =
135.1 Hz) (CH-P), 11.2 (N(CH2CH3)2);
31P NMR (81 MHz,
CD3OD) d 26.69. MS (MALDI-TOF) m/z calculated for
C80H121N7O28PS2: 1722.74, obtained: 1722.61; calculated for
C80H120NaN7O28PS2: 1744.74, obtained: 1744.63.
Compound 56. Starting from 55 (0.1 g, 0.03 mmol), 56 was
obtained (0.028 mmol, 95%) as a dark yellow-green foam
without further purification. 1H NMR (300 MHz, CD3OD) d
8.68 (s, 2H, ArTriazole-H), 8.57 (m, 2H, Ardye-2-H), 8.08 (m, 1H,
Ardye-6-H), 7.62–7.55 (d, 8H, J = 9.2 Hz, Ardye-AA0-H), 7.48 (d,
2H, J = 8.0 Hz, Ardye-5-H), 7.38–7.30 (m, 8H, Ardye-BB0-H), 7.27
(s, 4H, Ar2-2,6-H), 6.53 (m, 2H, Ar1-2,6-H), 6.45 (m, 1H, Ar1-4-H),
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5.41 (s, 4H, OCH2ArTriazole-CH2), 4.84 (t, J = 4.6 Hz, 4H, OCH2-
ArTriazole-CH2), 4.22 (m, 8H, Ar
2OCH2CH2), 4.18–4.11 (m, 4H,
Ar1OCH2CH2NH), 3.98 (t, J = 4.6 Hz, 4H, CH2CH2NHO2),
3.90–3.84 (m, 12H, OCH2CH2O, Ar
1OCH2CH2NH), 3.82–3.48
(m, 116H, OCH2CH2O and N(CH2CH3)2), 3.32 (s, 12H, OCH2-
CH2OCH3), 3.18 (t, J = 5.0 Hz, 4H, CH2CH2NHO2), 3.12 (d, J =
21.5 Hz, 2H, Ar1CH2P), 1.28 (t, J = 7.0 Hz, 24H, N(CH2CH3)2);
13C
NMR (75 MHz, CD3OD) d 166.7 (NHCO), 159.9 (Ar), 152.2
(Ardye = N), 145.7 (Ar), 142.6 (ArTriazole), 140.8 (Ar), 139.7
(Ar), 139.1 (Ar), 138.4 (Ar), 132.2 (Ar), 130.5 (Ar), 128.4 (Ar), 127.8
(ArTriazole), 126.6 (Ar), 124.8 (Ar), 119.1 (Ar), 108.9 (Ar), 106.2
(Ar), 72.1 (OCH2-ArTriazole), 71.6 (PEG), 70.7 (PEG), 70.6 (PEG),
70.55 (PEG), 70.5 (PEG), 70.45 (PEG), 70.4 (PEG), 69.5 (PEG),
69.3 (PEG), 68.5 (PEG), 68.2 (PEG), 66.2 (OCH2CH2NH), 62.8
(PEG), 60.7 (PEG), 57.8 (OCH3), 52.7 (ArTriazole-CH2), 48.5
(N(CH2CH3)2), 42.8 (CH2NHSO2), 39.3 (CH2NHCOAr), 33.1 ( J =
135.2 Hz) (CH-P), 11.2 (N(CH2CH2)2);
31P NMR (81 MHz,
CD3OD) d 23.91. MS (MALDI-TOF) m/z calculated for
C152H229N14O53PS4: 3259.74, obtained: 3260.41.
Compound 58. Starting from 57 (0.22 g, 0.11 mmol), 58 was
obtained (0.10 mmol, 98%) as a dark yellow-green foam without
further purification. 1H NMR (300 MHz, CD3OD) d 8.78 (s, 1H,
ArTriazole-H), 8.55 (m, 1H, Ardye-2-H), 8.11 (m, 1H, Ardye-6-H),
7.70–7.50 (m, 9H, Ardye-5-H, Ardye-AA0-H and Ardye-BB0-H),
7.30 (s, 2H, Ar2-2,6-H), 6.88 (m, 3H, Ar1-2,4,6-H), 5.51 (s, 2H,
OCH2ArTriazole-CH2), 4.91 (m, 2H, OCH2ArTriazole-CH2), 4.30
(m, 4H, Ar2OCH2CH2), 4.26 (m, 2H, Ar
1OCH2CH2NH), 4.04
(m, 2H, CH2CH2NHO2), 3.90–3.82 (m, 6H, OCH2CH2O and
Ar1OCH2CH2NH), 3.82–3.50 (m, 58H, OCH2CH2O and N(CH2-
CH3)2), 3.31 (s, 6H, OCH2CH2OCH3), 3.21 (d, J = 22.0 Hz, 4H,
Ar1CH2P), 3.19 (m, 2H, CH2CH2NHO2), 1.32 (m, 12H, N(CH2-
CH3)2);
13C NMR (75 MHz, CD3OD) d 167.8 (NHCO), 158.8 (Ar),
152.1 (Ardye = N), 142.7 (ArTriazole), 140.4 (Ar), 139.5 (Ar), 138.3
(Ar), 133.2 (Ar), 131.1 (Ar), 130.4 (Ar), 128.9 (Ar), 128.1 (Ar), 127.5
(ArTriazole), 126.2 (Ar), 123.7 (Ar), 123.3 (Ar), 120.2 (Ar), 114.8
(Ar), 106.2 (Ar), 72.1 (OCH2-ArTriazole), 71.5 (PEG), 70.7 (PEG),
70.6 (PEG), 70.5 (PEG), 70.4 (PEG), 69.4 (PEG), 69.2 (PEG), 68.5
(PEG), 67.8 (PEG), 66.1 (OCH2CH2NH), 62.5 (PEG), 60.9 (PEG),
57.8 (OCH3), 53.8 (ArTriazole-CH2), 48.4 (N(CH2CH3)2), 42.6
(CH2NHSO2), 39.5 (CH2NHCOAr), 33.8 ( J = 135.1 Hz) (CH-P),
11.2 (N(CH2CH3)2);
31P NMR (81 MHz, CD3OD) d 24.21. MS
(MALDI-TOF) m/z calculated for C81H123NaN7O31P2S2: 1838.72,
obtained: 1838.64.
Compound 60. Starting from 59 (0.2 g, 0.06 mmol), 60 was
obtained (0.058 mmol, 98%) as a dark yellow-green foam
without further purification. 1H NMR (300 MHz, CD3OD) d
8.82 (m, 2H, Ardye-2-H), 8.58 (s, 2H, ArTriazole-H), 8.14 (m, H,
Ardye-6-H), 7.72–7.47 (m, 18H, Ardye-5-H, Ardye-AA0-H and
Ardye-BB0-H), 7.31 (s, 4H, Ar3-2,6-H), 7.11 (m, 2H, Ar2-2,6-H),
6.95–6.88 (m, 3H, Ar1-2,4,6-H), 6.75 (m, 1H, Ar2-4-H), 5.48 (s, 4H,
OCH2ArTriazole-CH2), 4.91 (m, 4H, OCH2ArTriazole-CH2), 4.30–
4.15 (m, 14H, Ar1OCH2CH2NH, Ar
2OCH2CH2NH and Ar
2OCH2-
CH2), 4.02 (m, 4H, CH2CH2NHO2), 3.85–3.70 (m, 14H, OCH2-
CH2O, Ar
1OCH2CH2NH and Ar
2OCH2CH2NH), 3.75–3.45 (m, 116H,
OCH2CH2O and N(CH2CH3)2), 3.34 (s, 12H, OCH2CH2OCH3),
3.22–3.12 (m, 8H, CH2CH2NHO2 and Ar
1CH2P), 1.32 (m, 24H,
N(CH2CH3)2); 13C NMR (75 MHz, CD3OD) d 167.8 (NHCO), 159.9
(Ar), 158.6 (Ar), 151.9 (Ardye = N), 145.0 (Ar), 142.2 (ArTriazole),
140.0 (Ar), 139.5 (Ar), 138.3 (Ar), 135.5 (Ar), 133.4 (Ar), 131.8 (Ar),
130.1 (Ar), 128.3 (Ar), 127.9 (ArTriazole), 126.2 (Ar), 119.3 (Ar), 114.1
(Ar), 105.5 (Ar), 104.2 (Ar), 71.5 (OCH2-ArTriazole), 71.3 (PEG), 70.7
(PEG), 70.6 (PEG), 70.5 (PEG), 70.4 (PEG), 69.4 (PEG), 69.2 (PEG),
68.5 (PEG), 67.8 (PEG), 66.8 (OCH2CH2NH), 62.1 (PEG), 60.2 (PEG),
57.1 (OCH3), 53.2 (ArTriazole-CH2), 48.4 (N(CH2CH3)2), 42.3
(CH2NHSO2), 38.8 (CH2NHCOAr), 33.8 ( J = 135.1 Hz) (CH-P),
10.7 (N(CH2CH3)2);
31P NMR (81 MHz, CD3OD) d 25.11. MS
(MALDI-TOF) m/z calculated for C163H243N15O58P2S4: 3530.95,
obtained: 3530.84.
Part II: click-chemistry with phosphonates
Compound 67. Sodium azide (0.9 g, 13.9 mmol) was added
to a solution of 66 (1.92 g, 6.94 mmol) in CH3CN (35 mL) and
the resulting mixture was refluxed for 16 h. The solvent was
then removed under pressure and the residue dissolved in
water. The aqueous phase was washed with EtOAc and the
organic layer was dried over MgSO4, filtered and concentrated
in vacuo to yield 67 (6.56 mmol, 95%) as yellow oil. 1H NMR
(300 MHz, CDCl3) d 7.35–7.25 (m, 4H, Ar), 4.32 (s, 2H, CH2N3),
4.01 (qt, 4H, J = 6.99 Hz, CH2CH3), 3.20 (d, 4H, J = 21.7 Hz,
CH2PO(OEt)2), 1.25 (dd, 3H, J = 7.02 and 6.99 Hz, CH3);
13C
NMR (75 MHz, CDCl3) d 133.8 ( J = 3.84 Hz, C Ar next to CH2N3),
131.8 ( J = 9.27 Hz, C Ar next to CH2PO(OEt)2), 130.0 ( J =
6.54 Hz, CH Ar next to CH2PO(OEt)2), 128.2 ( J = 2.72 Hz, CH
Ar next to CH2N3), 61.9 ( J = 6.54 Hz, CH2CH3), 54.1 (CH2N3),
34.1, 32.3 (d, J = 136.9 Hz, CH2PO(OEt)2), 16.1 ( J = 6.54 Hz,
CH3);
31P NMR (81 MHz, CDCl3) d 26.48; MS (MALDI-TOF) m/z
calculated for C12H18N303P 283.11, obtained [M + H]
+ = 284.13.
Compound 72. The preparation procedures and analytical
data are similar to those reported in the literature.22c
Compound 81. Propargylbromide (2.1mL, 19mmol) was added
to a solution of 21 (6.2 g, 16mmol) and K2CO3 (22.0 g, 160mmol) in
acetone (150 mL). A pinch of 18-crown-6 was added and the
resulting mixture was refluxed for 16 h. The solvent was then
removed in vacuo after filtration. The crude product was dissolved
in CH2Cl2 and the organic phase was washed with water, brine,
dried over MgSO4, filtered and concentrated in vacuo to yield 81
(13.4mmol, 84%). Colourless oil. 1H NMR (300MHz, CDCl3) d 6.85–
6.83 (m, 3H, H Ar), 4.67 (d, 2H, J = 2.19Hz, CH2 alkyne), 4.02 (qt, 8H,
J = 6.99 Hz, CH2CH3), 3.14, 3.06 (d, 2H, J = 21.93 Hz, CH2PO(OEt)2),
2.50 (dd, 1H, J = 2.43 and 2.40 Hz, H alkyne), 1.25 (dd, 12H, J = 4.59
and 7.02 Hz, CH3);
13C NMR (75 MHz, CDCl3) d 157.6 (C Ar next
to alkyne), 133.1 ( J = 11.45 Hz, C Ar next to CH2PO(OEt)2), 124.4
( J = 13.09 Hz, CHAr next to CH2PO(OEt)2), 114.8 ( J = 8.72 Hz, CH Ar
next to alkyne), 78.3 (C alkyne), 75.4 (CH alkyne), 61.9 ( J = 7.63 Hz,
CH2CH3), 55.7 (CH2 alkyne), 34.5, 32.6 ( J = 137.46 Hz, CH2PO-
(OEt)2), 16.2 ( J = 5.45 Hz, CH3);
31P NMR (81 MHz, CDCl3) d 26.63;
MS (MALDI-TOF) m/z calculated for C19H30O7P2 432.14, obtained
[M + H]+ = 434.12, [M + Na]+ = 455.09.
Bisphosphonic acid anchors final deprotection
The pegylated PAMAM dendrons were deprotected in the
last step to give the bisphosphonic acid anchors necessary for
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grafting onto nanoparticles. For dendron 75, two steps were
necessary to get the OH-functionalized bisphosphonic acid 92.
On the other hand, for dendrons 73, 74, 79, 80, 86, 87, 90 and
91, one step was enough to deprotect both of the esters and
obtain COOH-functionalized bisphosphonic acids 93–100.
Compound 92. A solution of tetrabutylammonium fluoride
(TBAF, 1 M) in THF (1.6 mL, 0.17 mmol) was added to a
solution of 75 (0.85 g, 0.58 mmol) in THF (6 mL). The reaction
mixture was stirred for 16 h at room temperature and quenched
with acetic acid (140 mL). The solvent was then removed
in vacuo. The crude product was directly purified by column
chromatography (SiO2, CH2Cl2/MeOH 90 : 10–80 : 20) to yield
the corresponding protected dialcohol (0.53 mmol, 75%).
Yellow oil. 1H NMR (300 MHz, CDCl3) d 7.74 (m, 2H, NH),
7.59 (s, 1H, H triazole), 7.20–7.11 (m, 3H, H Ar), 5.48 (s, 2H,
CH2N next to triazole), 4.00 (qt, 8H, J = 7.23 Hz, CH2CH3), 3.81–
3.51 (m, 30H, PEG, NCH2 PAMAM, CH2N PAMAM), 3.52 (q, 4H,
J = 5.25 and 10.53 Hz, CH2OH), 3.14, 3.07 (d, 2H, J = 21.93 Hz,
CH2PO(OEt)2), 2.75 (dd, 4H, J = 6.36 and 6.57 Hz, CONHCH2),
2.41 (dd, 4H, J = 6.36 and 6.33 Hz, CH2CONH), 1.23 (t, 12H,
J = 7.02 Hz, CH3);
13C NMR (75 MHz, CDCl3) d 171.1 (CONH),
143.0 ( J = 6.50 Hz, C Ar next to triazole), 134.4 ( J = 11.91 Hz, C
Ar next to CH2PO(OEt)2), 132.0 ( J = 13.00 Hz, CH Ar next to
CH2PO(OEt)2), 130.4 (C alkyne), 127.0 ( J = 9.21 Hz, CH Ar next
to triazole), 122.3 (CH alkyne), 72.1 (CH2CH2OH), 70.0 (PEG),
69.9 (PEG), 69.6 (PEG), 69.5 (PEG), 69.3 (PEG), 61.7 ( J = 7.05 Hz,
CH2CH3), 60.8 (CH2OH), 53.2 (CH2N next to triazole), 48.9
(NCH2 PAMAM), 47.4 (CH2N PAMAM), 38.7 (CH2CONH), 33.9,
32.1 (d, J = 136.54 Hz, CH2PO(OEt)2), 33.3 (CONHCH2), 16.2
( J = 5.96 Hz, CH3). An excess of bromotrimethylsilane (TMSBr,
2 mL, 15.3 mmol) was then added at room temperature to a
solution of bisphosphonate ester (0.51 g, 0.52 mmol) in CH2Cl2
(5 mL). The reaction mixture was stirred for 2 h then quenched
with MeOH. The solvent was evaporated under vacuum to give
92 (0.51 mmol, quant) without further purification. 1H NMR
(300 MHz, CD3OD) d 8.33 (s, 1H, H triazole), 7.27–7.21 (m, 3H,
H Ar), 5.66 (s, 2H, CH2N next to triazole), 5.66 (s, 2H, CH2N
PAMAM), 3.69–3.38 (m, 32H, PEG, NCH2 PAMAM, CH2OH),
3.19, 3.12 (d, 2H, J = 21.93 Hz, CH2PO(OH)2), 2.86 (m, 4H,
CONHCH2), 2.67 (m, 4H, CH2CONH);
13C NMR (75 MHz,
CD3OD) d 171.9 (CONH), 136.7 (C Ar next to triazole), 134.2
(C Ar next to CH2PO(OH)2), 132.3 (CH Ar next to CH2PO(OH)2,
C alkyne), 129.1 (CH Ar next to triazole, CH alkyne), 73.1
(CH2CH2OH), 70.9 (PEG), 70.8 (PEG), 69.9 (PEG), 61.9 (CH2OH),
54.6 (CH2N next to triazole), 50.86 (NCH2 PAMAM), 47.5 (CH2N
PAMAM), 40.3 (CH2CONH), 35.5, 33.7 (d, 4H, J = 134.18 Hz,
CH2PO(OH)2), 29.9 (CONHCH2);
31P NMR (81 MHz, CD3OD)
d 25.76; MS (MALDI-TOF) m/z calculated for C34H60N6O16P2
870.35, obtained [M + H]+ = 871.31.
General procedure for the conversion of phosphonate ester to
phosphonic acid by TMSBr (McKenna’s method28) (93–100)
TMSBr (30 equiv.) was added at room temperature to a solution
of bisphosphonate ester 73, 74, 79, 80, 86, 87, 90 or 91 (1 equiv.)
in CH2Cl2 (5 mL). The reaction mixture was stirred for 2 h
then quenched with MeOH. The solvent was evaporated under
vacuum 3 times to give the desired compound without further
purification.
Compound 93. Starting from 73 (0.15 g, 0.14 mmol), com-
pound 93 was obtained (0.13 mmol, 98%). Yellow oil. 1H NMR
(300 MHz, CD3OD) d 8.46 (s, 1H, CH triazole), 7.36 (s, 4H, Ar),
5.68 (s, 2H, CH2N triazole), 4.66 (s, 2H, CH2N PAMAM), 3.74
(dd, 4H, J = 6.15 and 5.91 Hz, CH2CH2COOH), 3.70–3.34
(m, 36H, PEG), 3.25, 3.18 (d, 2H, J = 21.93 Hz, CH2PO(OH)2),
2.62 (dd, 4H, J = 5.19 and 6.12 Hz, CH2COOH);
13C NMR
(75 MHz, CDCl3) d 172.4 (COOH), 170.7 (CONH), 135.9 (C Ar
next to triazole), 133.7 ( J = 2.73 Hz, C Ar next to CH2PO(OH)2),
133.1 (C triazole), 130.3 ( J = 6 Hz, CH Ar next to CH2PO(OH)2),
128.1 ( J = 2.18 Hz, CH Ar next to triazole), 127.3 (CH Ar next to
triazole), 127.3 (CH triazole), 70.2 (PEG), 70.1 (PEG), 70.0 (PEG),
69.9 (PEG), 69.0 (CONHCH2CH2O), 66.3 (CH2CH2COOH), 53.5
(CH2N PAMAM), 49.9 (CH2N triazole), 46.4 (NCH2 PAMAM),
39.1 (CONHCH2), 34.3 (CH2COOH), 34.4, 32.9 ( J = 133.64 Hz,
CH2PO(OH)2), 28.6 (CH2COOH);
31P NMR (81 MHz, CD3OD)
d 25.10; MS (MALDI-TOF) m/z calculated for 920.41, obtained
[M + H]+ = 921.36.
Compound 94. The preparation procedures and analytical
data are reported in the literature.22c
Compound 95. Starting from 79 (0.19 g, 0.29 mmol),
compound 95 was obtained (0.29 mmol, 98%) as an yellow oil.
1H NMR (300 MHz, CD3OD) d 8.41 (s, 1H, H triazole), 7.31 (m, 3H,
H Ar), 5.73 (s, 2H, CH2N next to triazole), 4.76 (s, 2H, CH2O next to
triazole), 3.73–3.52 (m, 12H, PEG), 3.35 (s, 3H, OCH3), 3.25, 2.18
(d, 4H, J = 21.93 Hz, CH2PO(OH)2);
13C NMR (75 MHz, CD3OD)
d 141.6 (C triazole), 134.0 ( J = 10.16 Hz, C Ar next to triazole), 132.8
(C Ar next to CH2PO(OH)2), 131.7 ( J = 11.77 Hz, CH Ar next to
CH2PO(OH)2), 128.2 ( J = 8.55 Hz, CH Ar next to triazole), 126.2 (CH
triazole), 73.0 (CH2OCH3), 72.3 (PEG), 71.2 (PEG), 71.1 (PEG), 69.8
(PEG), 71.0 (PEG), 70.9 (PEG), 70.8 (PEG), 70.7 (PEG), 62.6 (CH2-
OCH2CH2O next to triazole), 61.8 (CH2O next to triazole), 58.8
(OCH3), 57.0 (CH2N next to triazole), 36.4, 34.7 (d, J = 131.07 Hz,
CH2PO(OH)2);
31P NMR (81 MHz, CD3OD) d 25.15; MS (MALDI-
TOF)m/z calculated for C19H31N3O10P2 523.14, obtained [M + H]
+ =
524.03, [M + Na]+ = 545.99, [M + K]+ = 561.94.
Compound 96. Starting from 80 (0.17 g, 0.18 mmol),
compound 96 was obtained (0.18 mmol, 99%) as an orange
oil. 1H NMR (300 MHz, CD3OD) d 8.67 (s, 1H, CH triazole), 7.36
(s, 3H, H Ar), 5.86 (s, 2H, CH2N next to triazole), 4.84 (s, 2H,
CH2O triazole), 3.77–3.52 (m, 36H, PEG), 3.35 (s, 3H, OCH3),
3.25, 3.18 (d, 4H, J = 21.93 Hz, CH2PO(OH)2), 2.57 (t, 2H, J = 6.15
Hz, CH2COOH);
13C NMR (75 MHz, CD3OD) d 141.7 (C triazole),
134.0 ( J = 9.09 Hz, C Ar next to triazole), 132.9 (C Ar next to
CH2PO(OH)2), 131.8 ( J = 5.34 Hz, CH Ar next to CH2PO(OH)2),
128.3 (CH Ar next to triazole), 126.4 (CH triazole), 73.0
(CH2OCH3), 72.4 (PEG), 71.2 (PEG), 70.9 (PEG), 70.9 (PEG),
62.6 (CH2OCH2CH2O next to triazole), 61.9 (CH2O next to
triazole), 58.9 (OCH3), 57.0 (CH2N next to triazole), 36.5, 34.7
(d, J = 130.53 Hz, CH2PO(OH)2);
31P NMR (81 MHz, CD3OD)
d 25.08; MS (MALDI-TOF) m/z calculated for C31H55N3O16P2
787.30, obtained [M + H]+ = 788.13,[M + Na]+ = 810.09.
Compound 97. Starting from 86 (0.68 g, 0.87 mmol), com-
pound 97 was obtained (0.85 mmol, 98%). Yellow oil. 1H NMR
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(300 MHz, CD3OD) d 8.53 (s, 1H, CH triazole), 6.98 (s, 3H, Ar),
4.79 (dd, 2H, J = 5.04 and 4.62 Hz, OCH2 triazole), 4.04 (dd, 2H,
J = 5.25 and 4.62 Hz, NCH2 triazole), 3.79–3.64 (m, 16H, PEG),
3.23, 3.16 (d, 4H, J = 21.93 Hz, CH2PO(OH)2), 2.63 (t, 2H, J = 6.12
Hz, CH2COOH);
13C NMR (75 MHz, CD3OD) d. 173.7 (COOH),
158.7 (C Ar next to triazole), 141.2 (C triazole), 135.5 ( J = 12 Hz,
C Ar next to CH2PO(OH)2), 129.0 (CH triazole), 126.1 ( J = 6.00 Hz,
CH Ar next to CH2PO(OH)2), 115.9 (CH Ar next to triazole), 71.2
(PEG), 71.1 (PEG), 71.0 (PEG), 69.0 (NCH2CH2O next to triazole),
67.4 (OCH2 next to triazole), 60.3 (NCH2CH2O), 54.1 (NCH2-
CH2O), 52.2 (CH2CH2COOH), 35.6 (CH2COOH), 36.0, 34.3 ( J =
133.09 Hz, CH2PO(OH)2);
31P NMR (81 MHz, CDCl3) d 25.77; MS
(MALDI-TOF) m/z calculated for C22H35N3O13P2 611.16, obtained
[M + H]+ = 612.12.
Compound 98. Starting from 87 (0.53 g, 0.56 mmol),
compound 98 was obtained (0.54 mmol, 97%) as a Burgundy oil.
1H NMR (300MHz, CD3OD) d 8.35 (s, 1H, CH triazole), 6.95 (bs, 3H,
Ar), 5.28 (s, 2H, OCH2 triazole), 4.71 (dd, 2H, J = 4.80 and 4.83 Hz,
NCH2 triazole), 3.99 (dd, 2H, J = 5.04 and 4.80 Hz, NCH2CH2O
triazole), 3.82–3.66 (m, 26H, PEG), 3.20, 3.13 (d, 4H, J = 21.48 Hz,
CH2PO(OH)2), 2.65 (dd, 2H, J = 6.15 and 6.12 Hz, CH2COOH);
13C
NMR (75 MHz, CD3OD) d 173.7 (COOH), 158.9 ( J = 2.73 Hz, C Ar
next to triazole), 135.7 ( J = 9.27Hz, C Ar next to CH2PO(OH)2), 153.2
(C triazole), 126.0 ( J = 6.54 Hz, CH Ar next to CH2PO(OH)2), 125.4
(CH triazole), 115.9 (CH Ar next to triazole), 71.3 (PEG), 71.1 (PEG),
69.3 (NCH2CH2O next to triazole), 67.4 (OCH2 next to triazole), 60.7
(NCH2CH2O), 53.6 (NCH2CH2O), 52.2 (CH2CH2COOH), 35.6
(CH2COOH), 36.3, 34.5 ( J = 133.0 Hz, CH2PO(OH)2);
31P NMR
(81 MHz, CDCl3) d 25.79; MS (MALDI-TOF) m/z calculated for
C30H51N3O17P2 787.26, obtained [M + H]
+ = 788.12.
Compound 99. Starting from 90 (0.37 g, 0.84 mmol), com-
pound 99 was obtained (0.69 mmol, 83%). Orange oil. 1H NMR
(300 MHz, CDCl3) d 10.34 (s, 3H, PO(OH)2, COOH), 3.78–3.52
(m, 12H, PEG), 2.50 (qt, 2H, J = 4.38 Hz, CH2COOH), 2.17 (m, 2H,
CH2PO(OH)2);
13C NMR (75 MHz, CDCl3) d 172.1 (COOH), 70.5
(PEG), 70.4 (PEG), 70.3 (PEG), 70.2 (PEG), 69.9 (PEG), 66.4
(CH2CH2COOH), 51.7 ( J = 5.45 Hz, OCH2CH2PO(OH)2), 34.7
(CH2COOH), 28.0, 26.2 ( J = 135.27 Hz, CH2PO(OH)2);
31P NMR
(81 MHz, CDCl3) d 33.18; MS (MALDI-TOF) m/z calculated for
C11H23O9P 330.10, obtained [M + H]
+ = 331.11, [M + Na]+ = 353.10.
Compound 100. Starting from 91 (0.09 g, 0.14 mmol), com-
pound 100 was obtained (0.14 mmol, 99%). Orange oil. 1H NMR
(300 MHz, CDCl3) d 9.61 (s, 3H, PO(OH)2, COOH), 3.84–3.42
(m, 32H, PEG), 2.55 (m, 2H, CH2COOH), 2.26 (m, 2H,
CH2PO(OH)2);
13C NMR (75 MHz, CDCl3) d 172.1 (COOH), 70.3
(PEG), 70.2 (PEG), 70.1 (PEG), 69.9 (PEG), 69.6 (PEG), 66.4
(CH2CH2COOH), 51.7 (OCH2CH2PO(OH)2), 34.7 (CH2COOH),
28.1, 26.3 ( J = 135.27 Hz, CH2PO(OH)2);
31P NMR (81 MHz,
CDCl3) d 29.03; MS (MALDI-TOF) m/z calculated for C19H39O13P
506.21, obtained [M + H]+ = 507.15, [M + Na]+ = 529.12.
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